Fusion proteins of tick anticoagulant peptide and staphylococcus aureus superantigen-like protein, preparation and application thereof

Abstract

The invention discloses a fusion protein of tick anticoagulant peptide and staphylococcus aureus superantigen-like-protein-5, and an amino acid sequence thereof comprises a first area which has at least 85 percent of similarity to a sequence shown in SEQ ID No.1 and a second area which has at least 85 percent of similarity to a sequence shown in SEQ ID No.2; the invention also discloses a gene for coding the fusion protein, a recombinant expression vector with the gene, a transformant with the recombinant expression vector and a method for preparing the fusion protein; the fusion protein has dual effects of anti-inflammatory and anticoagulation when PSGL-1 is used as a target, and does not affect the normal physiological functions of leucocytes while anti-inflammatory function is performed and does not cause bleeding complications due to excessive or wide anticoagulation while anticoagulation is carried out. The fusion protein can be used for preparing antiatherosclerotic drugs and anticoagulants and is hopeful in greatly improving the prevention and treatment levels of atherosclerosis and thromboembolic complications thereof, and is capable of reducing troubles and pains of sufferers, caused by respective drug administration of antiatherosclerotic drugs and anticoagulants.

Description

technical field [0001] The invention relates to a fusion polypeptide, in particular to a fusion protein of tick anticoagulant peptide and Staphylococcus aureus superantigen-like protein-5, its preparation method and application. Background technique [0002] Cardiovascular and cerebrovascular diseases based on atherosclerosis (ATS) are the main diseases that endanger human health. Its occurrence and development are related to inflammatory response or / and activation of coagulation system, and activation of coagulation system and inflammatory response can promote each other. At present, the therapeutic drugs for ATS only have a single anti-inflammatory or anticoagulant effect. In order to achieve a better therapeutic effect, a combination of drugs is often used clinically, but there are problems such as troublesome administration, patients' easy to miss doses, or poor compliance. So far, there is no research report on anti-ATS drugs with anti-inflammatory and anti-coagulant d...

AI Technical Summary

Problems solved by technology

Studies have found that SSL5 can specifically bind to PSGL-1, compete to antagonize the interaction between PSGL-1 and selectin, significantly inhibit the adhesion of leukocytes, and do not have the non-specific activation of the immune system by standard superantigens

Images